AJR Am J Roentgenol

1. PEACOCK JG, Franquet-Elia E, Harris AL, Weeks JG, et al
   A Practical Guide to PSMA PET Radiopharmaceuticals for Prostate Cancer Imaging, From the AJR Special Series on Molecular Imaging.
   AJR Am J Roentgenol. 2026 Jun 24. doi: 10.2214/AJR.26.34730.
   

   >> Share

   
   

   
   BMC Cancer

2. MA L, Fan L, Luo X, Huang Z, et al
   Exploring the relationship between potential hepatotoxicity and novel hormonal therapies in prostate cancer: a systematic review and meta-analysis.
   BMC Cancer. 2026 Jun 23. doi: 10.1186/s12885-026-16339.
   

   >> Share

   
   
3. DAI T, Xu Z, Wang H, Han W, et al
   Pharmacokinetics, safety, and efficacy of fuzuloparib in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: a phase 1 dose escalation and expansion study.
   BMC Cancer. 2026 Jun 25. doi: 10.1186/s12885-026-16182.
   

   >> Share

   
   

   
   BMC Urol

4. FRANZ T, Sicker T, Lueke J, Dinh B, et al
   To biopsy or not biopsy, that is the question - PI-RADS 3 prostate lesions - validation of clinical and radiological parameters for biopsy decision-making.
   BMC Urol. 2025;25:274.
   

   >> Share

   
   

   
   Cancer Imaging

5. CHO S, Seo HJ, Han H, Lee S, et al
   The feasibility of [(18)F]PSMA-1007 PET/CT for response assessment in prostate cancer following neoadjuvant androgen deprivation therapy compared with mpMRI.
   Cancer Imaging. 2026 Jun 23. doi: 10.1186/s40644-026-01073.
   

   >> Share

   
   

   
   Clin Cancer Res

6. MEDINA S, Tokuyama N, Putcha V, Pathak T, et al
   AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.
   Clin Cancer Res. 2026 Jun 26. doi: 10.1158/1078-0432.CCR-26-0871.
   

   >> Share

   
   

   
   Clin Imaging

7. PALUSZEK O, Almengo K, Saunders J, Pitsoulakis E, et al
   Availability, quality, and understandability of English and Spanish-language YouTube content on PSMA PET imaging for prostate cancer.
   Clin Imaging. 2026;137:110871.
   

   >> Share

   
   

   
   Eur Radiol

8. DIAS AB, Barentsz J, Allen C, Baroni RH, et al
   Prostate MRI quality improvement: a Roadmap from the ESUR Prostate MRI Working Group.
   Eur Radiol. 2026;36:5728-5744.
   

   >> Share

   
   
9. SUSHENTSEV N, Arya Z, Budd J, Frary A, et al
   AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study.
   Eur Radiol. 2026;36:5719-5727.
   

   >> Share

   
   
10. THORLEY N, Parry T, Brembilla G, Giganti F, et al
    Diagnostic accuracy of a 'stage-gated' approach for reporting prostate screening MRI: "Is less more?".
    Eur Radiol. 2026;36:5678-5687.
    

    >> Share

    
    
11. MESSINA E, Borrelli A, Mezzapesa F, Laschena L, et al
    Artificial intelligence-assisted reading of non-contrast prostate MRI: application and concordance with expert interpretation in a screening population within the PROSA trial.
    Eur Radiol. 2026;36:5690-5700.
    

    >> Share

    
    

    
    Eur Urol

12. MA H, Zhang L
    Re: Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men with Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE).
    Eur Urol. 2026 Jun 23:S0302-2838(26)02215-3. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

13. DUAN J, Zhu L, Cardan RA, Rong Y, et al
    Deformable Point Cloud Registration-Based Bidirectional Local Distance (DPCR-BLD): A Methodology for Systematic Evaluation and Visualization of Local Disagreements in Clinical Autocontouring.
    Int J Radiat Oncol Biol Phys. 2026;125:1258-1270.
    

    >> Share

    
    
14. NIKITAS J, Jamshidian P, Tree AC, Hall E, et al
    Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.
    Int J Radiat Oncol Biol Phys. 2026;125:1140-1148.
    

    >> Share

    
    
15. MEYER J, Zoberi JE, Kim H, Tran A, et al
    A National Survey of Medical Physicists: Part 1-Practice Patterns for High-Dose-Rate Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2026;125:1228-1240.
    

    >> Share

    
    
16. AL-HALLAQ HA, Zoberi JE, Tran A, Kim H, et al
    A National Survey of Medical Physicists: Part 2-Assessing Work Effort and Perceived Challenges and Satisfaction in HDR Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2026;125:1241-1251.
    

    >> Share

    
    

    
    J Clin Oncol

17. RIAZ IB, Rumble RB, Hope TA, Procopio G, et al
    Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2026 Jun 22:JCO2601001. doi: 10.1200/JCO-26-01001.
    

    >> Share

    
    
18. VASCOTTO IA, Antonica F, Roviello G, Antonuzzo L, et al
    Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2026 Jun 22:JCO2600658. doi: 10.1200/JCO-26-00658.
    

    >> Share

    
    

    
    J Nucl Med

19. KASHYAP R, Buteau JP, Papa N, Ayati N, et al
    Prognostic Value of Restaging [(18)F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Therapy.
    J Nucl Med. 2026 Jun 25:jnumed.126.272531. doi: 10.2967/jnumed.126.272531.
    

    >> Share

    
    

    
    J Urol

20. TYAGI P
    Letter: Testosterone Does Not Drive Prostate Cancer: Presenting the New Framework of Androgen Adequacy vs Inadequacy.
    J Urol. 2026 Jun 25:101097JU0000000000005160. doi: 10.1097/JU.0000000000005160.
    

    >> Share

    
    
21. CAMPBELL JA, Ali D, Rezaee ME, Jing Y, et al
    The Effect of Prostate Volume and 5-Alpha Reductase Inhibitor Use on Grade Progression and Treatment Decisions in Patients with Prostate Cancer on Active Surveillance.
    J Urol. 2026 Jun 24:101097JU0000000000005182. doi: 10.1097/JU.0000000000005182.
    

    >> Share

    
    

    
    PLoS One

22. OU Y, Ye C, Jiang H, Zhu Y, et al
    Tumor-associated M2 macrophages promote prostate cancer invasion through the M-CSF-PCLAF pathway.
    PLoS One. 2026;21:e0351858.
    

    >> Share

    
    

    
    Prostate

23. QUARTA L, Petix M, Filzmayer M, Orlandi F, et al
    Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity.
    Prostate. 2026 Jun 23. doi: 10.1002/pros.70211.
    

    >> Share

    
    

    
    Semin Oncol

24. PETRELLI F, Motta F, Bodrato S, De Stefani A, et al
    PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.
    Semin Oncol. 2026;53:152504.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share